US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gyre Therapeutics

8.40

-0.4800-5.41%

Post-market: 8.400.00000.00%16:05 EDT

Volume:161.06K

Turnover:1.40M

Market Cap:786.34M

PE:174.72

High:9.39

Open:8.72

Low:8.26

Close:8.88

Loading ...

Overview Company News Filings

Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury

MT Newswires Live

Gyre Therapeutics announces NMPA approval for trial on pirfenidone

BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces Nmpa Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

THOMSON REUTERS

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings

Simply Wall St.

Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings

Stock Track | Gyre Therapeutics Soars 7.12% Pre-Market on Profitability Turn and Revenue Beat

Stock Track | Gyre Therapeutics Soars 7.12% as 2024 Results Show Profitability Despite EPS Miss

Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases

MT Newswires Live

Gyre Therapeutics reports Q4 EPS 0c vs. ($1.39) last year

Gyre Therapeutics Q4 EPS $0.00 Up From $(1.39) YoY; Sales $27.87M Up From $27.15M YoY

Gyre Therapeutics Inc - Q4 Revenues $27.9 Million

THOMSON REUTERS

Gyre Therapeutics Q4 Operating Profit USD 665 Thousand

THOMSON REUTERS

Gyre Therapeutics Inc Outlook FY25 REV $118 Mln to $128 Mln

THOMSON REUTERS

Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target

MT Newswires Live

Gyre Therapeutics Inc : Noble Capital Initiates Coverage With Outperform Rating; Target Price $20

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":8.4,"timestamp":1745265600000,"preClose":8.88,"halted":0,"volume":161062,"hourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.4,"latestTime":"16:05 EDT","volume":946,"amount":7946.400000000001,"timestamp":1745265911064},"delay":0,"floatShares":16648400,"shares":93612442,"eps":0.048077,"marketStatus":"Post-Mkt","change":-0.48,"latestTime":"04-21 19:17:37 EDT","open":8.72,"high":9.385,"low":8.26,"amount":1395694.182309,"amplitude":0.126689,"askPrice":9.5,"askSize":250,"bidPrice":7.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.048077,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":8.88,"preHourTrading":{"tag":"盘前","latestPrice":8.61,"preClose":8.88,"latestTime":"06:55 EDT","volume":302,"amount":2563.409824,"timestamp":1745232913694},"postHourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.4,"latestTime":"16:05 EDT","volume":946,"amount":7946.400000000001,"timestamp":1745265911064},"volumeRatio":1.61533,"impliedVol":0.2912,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":16648400,"roa":"8.38%","roe":"20.24%","lyrEps":0.142017,"volumeRatio":1.61533,"shares":93612442,"dividePrice":0,"high":9.385,"amplitude":0.126689,"preClose":8.88,"low":8.26,"week52Low":6.11,"pbRate":"12.42","psRate":"7.44","week52High":19,"institutionHeld":0.0314,"latestPrice":8.4,"committee":-0.428571,"eps":0.048077,"divideRate":0,"volume":161062,"delay":0,"ttmEps":0.048077,"open":8.72,"prevYearClose":12.1,"prevWeekClose":8.88,"prevMonthClose":7.72,"prevQuarterClose":7.72,"fiveDayClose":7.52,"twentyDayClose":9.71,"sixtyDayClose":10.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523777940","title":"Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2523777940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523777940?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:06","pubTimestamp":1743430008,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis.The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at oncology and academic centers in China.Shares of the company were down 1.8% in recent Monday trading.Price: 8.95, Change: -0.16, Percent Change: -1.76","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2523910247","title":"Gyre Therapeutics announces NMPA approval for trial on pirfenidone","url":"https://stock-news.laohu8.com/highlight/detail?id=2523910247","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523910247?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:20","pubTimestamp":1743420029,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has approved it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-nmpa-approval-for-trial-on-pirfenidone?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-nmpa-approval-for-trial-on-pirfenidone?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2523891708","title":"BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523891708","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523891708?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:14","pubTimestamp":1743419692,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Announces NMPA Approval For Clinical Trial Evaluating Pirfenidone Capsules In Oncology-Related Pulmonary ComplicationsMarch 31 (Reuters) - Gyre Therapeutics Inc GYRE.O:GYRE THE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2523120369","title":"Gyre Therapeutics Announces Nmpa Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523120369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523120369?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:02","pubTimestamp":1743418979,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2523917982","title":"Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917982","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917982?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  31, 2025  (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the Nat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052154/0/en/Gyre-Therapeutics-Announces-NMPA-Approval-for-Clinical-Trial-Evaluating-Pirfenidone-Capsules-in-Oncology-Related-Pulmonary-Complications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2522539564","title":"We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539564?lang=en_us&edition=fundamental","pubTime":"2025-03-28 02:40","pubTimestamp":1743100810,"startTime":"0","endTime":"0","summary":"The stock price didn't jump after Gyre Therapeutics, Inc.  posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in the report.We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:GYRE Earnings and Revenue History March 27th 2025. To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Gyre Therapeutics increased the number of shares on issue by 9.7% over the last twelve months by issuing new shares. As a result, its net income is now split between a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out Gyre Therapeutics' historical EPS growth by clicking on this link.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-aware-concerning-factors-gyre-184010501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","GYRE",".IXIC","AWRE"],"gpt_icon":0},{"id":"2522379864","title":"Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379864?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:20","pubTimestamp":1743074411,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chroni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-publication-of-protocol-for-phase-3-trial-on-f351?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-publication-of-protocol-for-phase-3-trial-on-f351?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2522375122","title":"Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375122","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375122?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Gyre Therapeutics  , an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in theJournal of Clinical and Translational Hepatology.This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B . The published protocol outlines patient inclusion criteria, randomization and blinding processes, key assessments, and the statistical analysis plan.The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial  completed the enrollment of 248 patients across 44 clinical research hospitals in the People’s Republic of China  in October 2024. Patients were randomized 1:1 to receive either F351","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gyre-therapeutics-announces-publication-protocol-110000523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GYRE","BK4139","CHB"],"gpt_icon":0},{"id":"2521444293","title":"Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2521444293","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521444293?lang=en_us&edition=fundamental","pubTime":"2025-03-21 12:08","pubTimestamp":1742530102,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q4 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-turnaround-in-2024-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-turnaround-in-2024-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"gpt_icon":0},{"id":"1186044367","title":"Stock Track | Gyre Therapeutics Soars 7.12% Pre-Market on Profitability Turn and Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1186044367","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186044367?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:32","pubTimestamp":1742391146,"startTime":"0","endTime":"0","summary":"Shares of Gyre Therapeutics  are soaring 7.12% in pre-market trading on Wednesday following the release of its Full Year 2024 financial results. The biotechnology company has shown significant improvement in its financial performance, turning profitable despite a slight decline in revenue.Gyre Therapeutics reported revenue of $105.8 million for the full year 2024, down 6.8% from the previous year but beating analyst estimates by 4.3%. The company achieved profitability with a net income of $12.1","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GYRE"],"gpt_icon":0},{"id":"1145098371","title":"Stock Track | Gyre Therapeutics Soars 7.12% as 2024 Results Show Profitability Despite EPS Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1145098371","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145098371?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:32","pubTimestamp":1742391143,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  stock is soaring 7.12% in early trading on Wednesday following the release of its full-year 2024 financial results. The biotech company reported a significant turnaround, moving from a net loss in 2023 to profitability in 2024, despite a slight decline in revenue.According to the report, Gyre Therapeutics generated revenue of $105.8 million, down 6.8% from the previous year but exceeding analyst estimates by 4.3%. The company posted a net income of $12.1 million, a substantial","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Gyre Therapeutics Soars 7.12% as 2024 Results Show Profitability Despite EPS Miss","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GYRE"],"gpt_icon":0},{"id":"2520686381","title":"Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2520686381","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520686381?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:50","pubTimestamp":1742244650,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  reported Q4 breakeven late Monday, compared with a net loss of $1.39 per diluted share a year earlier.One analyst polled by FactSet expected earnings of $0.04 per share.Revenue for the quarter ended Dec. 31 was $27.9 million, up from $27.1 million a year earlier.One analyst surveyed by FactSet expected $23.5 million.The company said it expects 2025 revenue between $118 million and $128 million.One analyst polled by FactSet expects $135.7 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"gpt_icon":0},{"id":"2520685767","title":"Gyre Therapeutics reports Q4 EPS 0c vs. ($1.39) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520685767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520685767?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:36","pubTimestamp":1742243801,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and clinical-stage...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q4-eps-0c-vs-1-39-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q4-eps-0c-vs-1-39-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"gpt_icon":0},{"id":"2520880936","title":"Gyre Therapeutics Q4 EPS $0.00 Up From $(1.39) YoY; Sales $27.87M Up From $27.15M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520880936","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520880936?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:19","pubTimestamp":1742242749,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported $27.87 million in sales this quarter. This is a 2.67 percent increase over sales of $27.15 million the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44364632/gyre-therapeutics-q4-eps-0-00-up-from-1-39-yoy-sales-27-87m-up-from-27-15m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Gyre Therapeutics Q4 EPS $0.00 Up From $(1.39) YoY; Sales $27.87M Up From $27.15M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2520193688","title":"Gyre Therapeutics Inc - Q4 Revenues $27.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520193688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520193688?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q0122:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2520688677","title":"Gyre Therapeutics Q4 Operating Profit USD 665 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688677?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nPLX974574:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2520141688","title":"Gyre Therapeutics Inc Outlook  FY25 REV $118 Mln to $128 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2520141688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520141688?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nPLX974574:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2520688254","title":"Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688254?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242500,"startTime":"0","endTime":"0","summary":"Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025. Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025. Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025. \"2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and clinical-stage portfolios. We plan to expand and enhance our commercial product offerings through the additions of nintedanib for IPF, SSc-ILD and PF-ILD, as well as avatrombopag for CLD-associated thrombocytopenia and chronic idiopathic thrombocytopenia . Given our proven track record and extensive sales and marketing platform, we are confident in our ability to successfully launch and expand these two products in the PRC,\" said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. \"In parallel, we expect to share topline data from our pi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2518728385","title":"Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2518728385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518728385?lang=en_us&edition=fundamental","pubTime":"2025-03-11 22:42","pubTimestamp":1741704125,"startTime":"0","endTime":"0","summary":"Price: 11.12, Change: +0.79, Percent Change: +7.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE","NBL"],"gpt_icon":0},{"id":"2518740236","title":"Gyre Therapeutics Inc : Noble Capital Initiates Coverage With Outperform Rating; Target Price $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2518740236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518740236?lang=en_us&edition=fundamental","pubTime":"2025-03-11 22:04","pubTimestamp":1741701861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU18N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null},{"market":"US","date":"2024-11-13","symbol":"GYRE","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":0.02},{"market":"US","date":"2024-08-13","symbol":"GYRE","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":0.01},{"market":"US","date":"2024-05-09","symbol":"GYRE","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-04-17","current":61.504575,"percent":0.955102,"low":-11548.718266,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"high":95.122945,"avg":-1400.455177,"sd":3328.303917,"marketCap":743282789},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789}],"updateTime":1745277457887}}}